SI-B037-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B037 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies
Study Identifier:
SI-B037-ST-101
CT.gov Identifier:
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
Will Be Recruiting
Considering participating in a START clinical trial?
Study Summary
The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.
Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
N/A
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase I
Sex
Female & Male
Age
18+ years
Study Drug
Drug: EXPERIMENTAL: Experimental: Experimental SI-B037
Read More
Drug: SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks
Drug: Drug: SI-B037
Study Status
Indicates the current recruitment status or the expanded access status
Will Be Recruiting
Requirements information
Inclusion criteria
- * Signed the informed consent form voluntarily and agreed to follow the trial requirements.
- * Male or Female Age ≥18 years.
- * Has a life expectancy of ≥3 months.
- * Subjects with documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standard therapy in the metastatic setting.
- * At least 1 measurable lesion based on RECIST 1.1
- * Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
- * Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V6.0.
- * Has no serious cardiac dysfunction and left ventricular ejection fraction ≥50%.
- * Has adequate organ function, before enrollment
- * Sexually active fertile participants and their partners must agree to use highly effective methods of contraception (defined in Appendix 5 of the protocol) during the course of the study and for 4 months for men and 7 months for women after the last dose of study treatment.
- * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening and must be nonlactating.
Exclusion criteria
- Chemotherapy, biological therapy, immunotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; radical radiotherapy, major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral drugs such as capecitabine, or palliative radiotherapy within 2 weeks prior to initial administration.
- * Received systemic immunostimulatory therapy (such as IFN-α, IL-2) within 4 weeks prior to the first dose or is still within 5 half-lives of the treatment (whichever is longer).
- * Participants with history of severe heart disease, such as symptomatic congestive heart failure Grade ≥2 (CTCAE 6.0), New York Heart Association (NYHA) Grade ≥2 heart failure at any time, history of myocardial infarction, or unstable angina pectoris within 6 months before enrollment.
- * Grade ≥ 3 toxicity related to anti-angiogenic therapy (except for fever and other toxicities that the investigator believes does not pose a safety risk to trial participants) when receiving anti-angiogenic therapy in the past.
- * Participant with active or untreated hemorrhagic CNS lesions.
- * Participants with pre-existing Grade ≥2 peripheral neuropathy
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.
Study Locations
Location
Investigator
Status
Condition(s) Treated at Site
Location
START Mountain Region
West Valley City, UT, United States, 84119
Investigator
Jose Pacheco
Status
Will Be Recruiting
Condition(s) Treated at Site
Location
START Midwest
Grand Rapids, MI, United States, 49546
Investigator
Nehal Lakhani
Status
Will Be Recruiting
Condition(s) Treated at Site